Verteporfin clinical trials
Verteporfin is named as an intervention in 3 current clinical trials in our USA, UK, Sweden, Canada, Germany and Denmark registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is SpectraCure AB (2). The most-studied condition is Recurrent Prostate Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Verteporfin is approved
All regulators →Of the three regulators tracked here, the first to approve Verteporfin was the US, on 12 Apr 2000. It is approved in 3 of the 3 regulators tracked here.
- 2 EU safety letters (DHPC), latest: medicine shortage for Visudyne, 12 Aug 2022
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Verteporfin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Verteporfin works
All drug targets →- Visual impairmentPhase 3
- Age-related macular degenerationPhase 3
- Basal cell carcinomaPhase 3
- Choroidal neovascularizationPhase 3
- Malignant pancreatic neoplasmPhase 2
- Pancreatic neoplasmPhase 2
- Breast cancerPhase 1/2
- Central serous retinopathyPhase 1/2
- FibrosisPhase 1/2
- GlioblastomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314346, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Verteporfin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 1 product on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: VisudyneEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Verteporfin
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
SCARFREE-001: Verteporfin for Scar Prevention
NCT07488988 · ClinicalTrials.gov ↗ · Surgical Scar
|
Phase 2 | Recruiting | Odense University Hospital | Denmark |
|
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
NCT03067051 · Recurrent Prostate Cancer
|
Phase 1/2 | Recruiting | SpectraCure AB | UK, USA, Sweden, Canada |
|
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
NCT06807359 · Prostate Cancer
|
Phase 1/2 | Recruiting | SpectraCure AB | USA, Germany |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Verteporfin in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Verteporfin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
SCARFREE-001: A Phase 2 Dose-Finding and Proof-of-Concept Study of Intradermal Verteporfin for Scar Prevention in Open and Closed Surgical Wounds
2025-525083-14-00 · CTIS ↗ · Therapeutics
|
Phase 2 | Authorised | Odense University Hospital | Denmark |
Verteporfin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
1 single-substance product containing Verteporfin on the HPRA medicines list.
- Visudyne 15 mg powder for solution for infusionCHEPLAPHARM Arzneimittel GmbH · EU/1/00/140/001
Supply shortages
- VisudyneEU (EMA) · Shortage ongoing · first published 8 Nov 2021
- Visudyne 15 mg Pulver zur Herstellung einer Infusionslösung - OP1Germany (BfArM) · Other reason · 1 Jul 2021 to 31 Dec 2026
Conditions studied with Verteporfin
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| SpectraCure AB | 2 |
| Odense University Hospital | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in Sweden | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in Denmark | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Verteporfin trials
How many clinical trials are testing Verteporfin?
3 current trials in our USA, UK, Sweden, Canada, Germany and Denmark registers name Verteporfin as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Verteporfin trials recruiting patients?
Yes. 3 of the 3 trials are recruiting: 2 with sites in USA, 1 with sites in UK, 1 with sites in Sweden, 1 with sites in Canada, 1 with sites in Germany and 1 with sites in Denmark. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Verteporfin clinical trials?
SpectraCure AB (2) and Odense University Hospital (1). The number in brackets is how many trials each organisation leads.
Is Verteporfin licensed in Ireland?
Yes. The HPRA medicines list includes 1 single-substance product containing Verteporfin, for example Visudyne 15 mg powder for solution for infusion (CHEPLAPHARM Arzneimittel GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Verteporfin shortage?
The registers we track list 2 entries for Verteporfin: Visudyne (EU: shortage ongoing); 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Verteporfin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Verteporfin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Verteporfin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.